Document Detail


Methionine synthase polymorphism A2756G is associated with susceptibility for thromboembolic events and altered B vitamin/thiol metabolism.
MedLine Citation:
PMID:  12091127     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVES: Vitamin B12 dependent methionine synthase (MS) regulates de novo production of methionine from homocysteine (Hcy). Since moderate elevations in Hcy are considered vasculotoxic, we examined a common variant (A2756G-MS) of the gene coding for this enzyme as a risk for thromboembolism. DESIGN AND METHODS: We investigated A2756G-MS and folate/thiol status in 51 individuals who had experienced a thromboembolic event (TE) and 95 subjects being treated for non-thromboembolic (NTE) vascular problems. RESULTS: The prevalence of the mutant G allele was lower in TE subjects than in controls, indicating a protective role for this base substitution (OR 0.39; 95%CI 0.20-0.78; p=0.010). Consistent with an advantage conferred by this allele, heterozygotes had generally lower levels of Hcy and glutathione (GSH), and higher levels of B-vitamins than wildtypes. The OR for the wildtype having an increased risk for TE was 2.32 (95%CI 1.06-5.08). Additionally, as might be predicted, TE-wildtypes had elevated GSH levels compared to corresponding NTE-wildtypes (p=0.004) - a likely response to oxidative stress. NTE subjects showed a dramatic reduction in Hcy between wildtype and heterozygote (p=0.017), and again between recessive and heterozygote genotypes (p=0.002). The same pattern, although not significant, occurred in TE subjects. The similarity in Hcy between clinical groups for each genotype raises questions on the etiological role of Hcy in TE. The functional relationship between enzyme variant and its B12-cofactor may be of more interest, since the polymorphic site occurs near the B12-binding domain, and our results indicate wildtype-TE subjects have a much lower level of vitamin B12 than heterozygote-TE subjects (p=0.0019). This effect is attenuated in NTE subjects. INTERPRETATION AND CONCLUSIONS:. A2756G-MS may protect against a thromboembolic event. The role of Hcy remains unclear.
Authors:
Zoe Yates; Mark Lucock
Related Documents :
22427347 - Competing risk analyses: how are they different and why should you care?
22540367 - Is apolipoprotein e e4 allele always hazardous? serum uric acid level as a conflict.
22356597 - Trends in health behaviors in the old-old population: results from a national survey.
22392517 - Feederism: an exaggeration of a normative mate selection preference?
16508717 - Epidemiology of traumatic brain injury and subarachnoid hemorrhage.
22850167 - Prevalence of anal incontinence among norwegian women: a cross-sectional study.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Haematologica     Volume:  87     ISSN:  0390-6078     ISO Abbreviation:  Haematologica     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-01     Completed Date:  2003-07-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  751-6; discussion 756     Citation Subset:  IM    
Affiliation:
University of Leeds, West Yorkshire, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / genetics*
Aged
Genetic Predisposition to Disease
Glutathione / blood
Homocysteine / blood
Humans
Male
Middle Aged
Polymorphism, Single Nucleotide / physiology*
Prevalence
Sulfhydryl Compounds / metabolism
Thromboembolism / blood,  enzymology,  genetics*
Vitamin B 12 / metabolism*
Chemical
Reg. No./Substance:
0/Sulfhydryl Compounds; 454-28-4/Homocysteine; 68-19-9/Vitamin B 12; 70-18-8/Glutathione; EC 2.1.1.13/5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns.
Next Document:  Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.